108 Participants Needed

RN0361 for High Triglycerides

Recruiting at 8 trial locations
EJ
Dx
AJ
Overseen ByAmy J zhu

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called RN0361, an experimental therapy, to assess its safety and effectiveness for individuals with high triglycerides, a type of fat in the blood. The trial has two phases: it begins with healthy adults and then shifts focus to those with very high triglycerides. Ideal candidates have long struggled with triglyceride levels, particularly those over 300 mg/dL. Participants will receive either the RN0361 injection or a placebo to compare results. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

Do I have to stop taking my current medications for the trial?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the study team to get a clear answer.

Is there any evidence suggesting that RN0361 is likely to be safe for humans?

Research has shown that RN0361 was safe in earlier studies. Participants who took RN0361 experienced lower triglyceride levels (a type of fat in the blood) without major safety issues. No significant side effects were reported, indicating the treatment is generally well-tolerated. This study includes both healthy adults and those with high triglycerides to further assess the safety of RN0361. Current testing suggests it is relatively safe for people, but ongoing studies will provide more detailed information.12345

Why do researchers think this study treatment might be promising?

Unlike the standard treatments for high triglycerides, which often include lifestyle changes, statins, or fibrates, RN0361 is unique because it uses subcutaneous injections to deliver its effects. This method could potentially offer more direct and efficient control over triglyceride levels. Researchers are also excited about RN0361 because it might work through a novel mechanism that targets triglycerides differently than existing medications, offering hope for patients who haven't responded well to current options.

What evidence suggests that RN0361 might be an effective treatment for high triglycerides?

Research shows that RN0361, which participants in this trial may receive, may help lower triglyceride levels. This treatment, called siRNA, reduces a protein called ApoC3, which is linked to high triglyceride levels. In earlier studies, RN0361 significantly lowered both ApoC3 and triglycerides for up to six months. These early findings suggest that RN0361 could effectively manage high triglycerides.23567

Are You a Good Fit for This Trial?

This trial is for adults who are healthy or have high triglycerides, with specific blood fat levels. Participants must agree to study procedures and use effective contraception. They cannot donate sperm or eggs during the study.

Inclusion Criteria

I am not pregnant or breastfeeding and use effective birth control. Or, I ensure the use of contraception during the study.
I will not donate sperm or eggs during the study.
I am willing to sign a consent form for the study.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase 1 Treatment

Participants receive single ascending doses of RN0361 or placebo to evaluate safety, tolerability, and pharmacokinetics

Up to 12 weeks
Multiple visits for dosing and monitoring

Phase 2 Treatment

Participants receive a single dose of RN0361 or placebo to evaluate pharmacodynamic effects and immunogenicity

Up to 26 weeks
Regular visits for monitoring and assessments

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • RN0361
Trial Overview The trial tests RN0361's safety and effects on the body in healthy adults and those with high triglycerides. It involves a single dose of RN0361 to see how it's tolerated and how it affects the body's functions.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: RN0361Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Ikaria Bioscience Pty Ltd

Lead Sponsor

Trials
3
Recruited
120+

Citations

Rona Therapeutics Receives IND Clearance from FDA to ..."RN0361's Phase I data validate its potential as a best-in-class siRNA with durable efficacy and patient-friendly dosing. We look forward to ...
FDA Clears Rona Therapeutics' IND for Phase 2 Study of ...The upcoming global Phase 2 study will be randomized, double-blind, and placebo-controlled, evaluating RN0361's efficacy and safety over a nine-month follow-up ...
RN0361, an siRNA Directed Against ApoC3 Demonstrates ...Assessments of ApoB and LDL showed a trend to a decrease Conclusion: RN0361, a long acting and potent siRNA directed against ApoC3 was well ...
RN0361 for High TriglyceridesThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single doses of RN0361 in Adult ...
RN-0361 - Drug Targets, Indications, PatentsResults showed that the RN0191 group achieved up to 95% maximum reduction in PCSK9 and a 74% drop in LDL-C, with average reductions of 87% and 56%, respectively ...
NCT06471543 | Study of RN0361in Adult Healthy Subjects ...Fasting serum triglyceride levels > 80 mg/dL and fasting LDL-C ≥70 mg/dL at screening; Female participants must either be nonchildbearing or, if of childbearing ...
RN-0361 | Advanced Drug Monograph - MedPathComprehensive analysis about RN-0361, including its mechanisms, clinical uses, and therapeutic considerations.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security